460 related articles for article (PubMed ID: 35073561)
21. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
22. Identification of Potential Inhibitors against Epstein-Barr Virus Nuclear Antigen 1 (EBNA1): An Insight from Docking and Molecular Dynamic Simulations.
Jakhmola S; Jonniya NA; Sk MF; Rani A; Kar P; Jha HC
ACS Chem Neurosci; 2021 Aug; 12(16):3060-3072. PubMed ID: 34340305
[TBL] [Abstract][Full Text] [Related]
23. HLA DR2b-binding peptides from human endogenous retrovirus envelope, Epstein-Barr virus and brain proteins in the context of molecular mimicry in multiple sclerosis.
Ramasamy R; Mohammed F; Meier UC
Immunol Lett; 2020 Jan; 217():15-24. PubMed ID: 31689443
[TBL] [Abstract][Full Text] [Related]
24. Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
Jons D; Grut V; Bergström T; Zetterberg H; Biström M; Gunnarsson M; Vrethem M; Brenner N; Butt J; Blennow K; Nilsson S; Kockum I; Olsson T; Waterboer T; Sundström P; Andersen O
J Neurol Neurosurg Psychiatry; 2024 Mar; 95(4):325-332. PubMed ID: 37802637
[TBL] [Abstract][Full Text] [Related]
25. Computational analysis of EBNA1 "druggability" suggests novel insights for Epstein-Barr virus inhibitor design.
Gianti E; Messick TE; Lieberman PM; Zauhar RJ
J Comput Aided Mol Des; 2016 Apr; 30(4):285-303. PubMed ID: 27048620
[TBL] [Abstract][Full Text] [Related]
26. Strains of Epstein-Barr virus infecting multiple sclerosis patients.
Brennan RM; Burrows JM; Bell MJ; Bromham L; Csurhes PA; Lenarczyk A; Sverndal J; Klintenstedt J; Pender MP; Burrows SR
Mult Scler; 2010 Jun; 16(6):643-51. PubMed ID: 20350958
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus candidate genes and multiple sclerosis.
Claire Simon K; Schmidt H; Loud S; Ascherio A
Mult Scler Relat Disord; 2015 Jan; 4(1):60-4. PubMed ID: 25787055
[TBL] [Abstract][Full Text] [Related]
28. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
29. EBNA1 and LMP1 variants in multiple sclerosis cases and controls.
Simon KC; Yang X; Munger KL; Ascherio A
Acta Neurol Scand; 2011 Jul; 124(1):53-8. PubMed ID: 20636447
[TBL] [Abstract][Full Text] [Related]
30. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein.
Bray PF; Luka J; Bray PF; Culp KW; Schlight JP
Neurology; 1992 Sep; 42(9):1798-804. PubMed ID: 1381067
[TBL] [Abstract][Full Text] [Related]
31. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
32. Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells.
Gottlieb A; Pham HPT; Saltarrelli JG; Lindsey JW
Proc Natl Acad Sci U S A; 2024 Jan; 121(3):e2315857121. PubMed ID: 38190525
[TBL] [Abstract][Full Text] [Related]
33. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
van Nierop GP; Mautner J; Mitterreiter JG; Hintzen RQ; Verjans GM
Mult Scler; 2016 Mar; 22(3):279-91. PubMed ID: 26041797
[TBL] [Abstract][Full Text] [Related]
34. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G; Münz C
J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
[TBL] [Abstract][Full Text] [Related]
35. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer.
Soldan SS; Anderson EM; Frase DM; Zhang Y; Caruso LB; Wang Y; Deakyne JS; Gewurz BE; Tempera I; Lieberman PM; Messick TE
Gastric Cancer; 2021 Sep; 24(5):1076-1088. PubMed ID: 33929613
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus in multiple sclerosis.
Abdelrahman HS; Selim HS; Hashish MH; Sultan LI
J Egypt Public Health Assoc; 2014 Aug; 89(2):90-5. PubMed ID: 25162741
[TBL] [Abstract][Full Text] [Related]
37. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
38. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
39. Association of Epstein-Barr virus infection with multiple sclerosis in India.
Pandit L; Malli C; D'Cunha A; Shetty R; Singhal B
J Neurol Sci; 2013 Feb; 325(1-2):86-9. PubMed ID: 23312038
[TBL] [Abstract][Full Text] [Related]
40. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma.
Sivachandran N; Dawson CW; Young LS; Liu FF; Middeldorp J; Frappier L
J Virol; 2012 Jan; 86(1):60-8. PubMed ID: 22013060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
